NCT Code,Trial Name,Trial URL,Priority,Status
NCT05254184,KRAS-Targeted Vaccine With Nivolumab and Ipilimumab for Patients With NSCLC,https://clinicaltrials.gov/study/NCT05254184,2. Multi-RAS + Colon,RECRUITING
NCT05438667,TCR-T Cell Therapy on Advanced Solid Tumors,https://clinicaltrials.gov/study/NCT05438667,2. Multi-RAS + Colon,RECRUITING
NCT06253520,Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer,https://clinicaltrials.gov/study/NCT06253520,2. Multi-RAS + Colon,RECRUITING
NCT06667544,A Study of RNK08954 in Subjects With Advanced Solid Tumors With KRAS ((Kirsten Rat Sarcoma) G12D Mutation,https://clinicaltrials.gov/study/NCT06667544,2. G12D + Basket trial,RECRUITING
NCT06947811,A Study of Almonertinib Combined With Palbociclib in Patients With Advanced Solid Tumors Harboring KRAS Mutations,https://clinicaltrials.gov/study/NCT06947811,2. Multi-RAS + Colon,RECRUITING
NCT06956261,NW-301 TCR-T in Patients With Advanced Solid Tumor,https://clinicaltrials.gov/study/NCT06956261,2. Multi-RAS + Colon,NOT_YET_RECRUITING
NCT06970132,Study of SY-5933 Plus CT-707 in Advanced Solid Tumors With KRAS p.G12C Mutation,https://clinicaltrials.gov/study/NCT06970132,2. Multi-RAS + Colon,NOT_YET_RECRUITING
NCT07207707,A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies,https://clinicaltrials.gov/study/NCT07207707,2. Multi-RAS + Colon,RECRUITING
NCT07240766,HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation,https://clinicaltrials.gov/study/NCT07240766,2. G12D + Basket trial,NOT_YET_RECRUITING
NCT07259590,A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation,https://clinicaltrials.gov/study/NCT07259590,2. G12D + Basket trial,RECRUITING
NCT03745326,Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients,https://clinicaltrials.gov/study/NCT03745326,2. G12D + Basket trial,RECRUITING
NCT05786924,Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies,https://clinicaltrials.gov/study/NCT05786924,2. Multi-RAS + Colon,RECRUITING
NCT06040541,Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors,https://clinicaltrials.gov/study/NCT06040541,2. G12D + Basket trial,RECRUITING
NCT06218914,"Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors",https://clinicaltrials.gov/study/NCT06218914,2. G12D + Basket trial,RECRUITING
NCT06403735,A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors,https://clinicaltrials.gov/study/NCT06403735,2. G12D + Basket trial,RECRUITING
NCT06445062,Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors,https://clinicaltrials.gov/study/NCT06445062,2. Multi-RAS + Colon,RECRUITING
NCT06487377,IX001 TCR-T In the Treatment of Advanced Pancreatic Cancer and Colorectal Cancer Induced by KRAS Mutations,https://clinicaltrials.gov/study/NCT06487377,2. Multi-RAS + Colon,RECRUITING
NCT06586515,"MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors",https://clinicaltrials.gov/study/NCT06586515,2. G12D + Basket trial,RECRUITING
NCT06607185,A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors,https://clinicaltrials.gov/study/NCT06607185,2. Multi-RAS + Colon,RECRUITING
NCT06917079,BBO-11818 in Adult Subjects With KRAS Mutant Cancer,https://clinicaltrials.gov/study/NCT06917079,2. Multi-RAS + Colon,RECRUITING
NCT07014878,A Study of DCTY1102 Injection in Patients With Advanced Solid Tumors,https://clinicaltrials.gov/study/NCT07014878,2. Multi-RAS + Colon,NOT_YET_RECRUITING
NCT07020221,A Phase 1/2a Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors,https://clinicaltrials.gov/study/NCT07020221,2. G12D + Basket trial,RECRUITING
NCT07094204,A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors,https://clinicaltrials.gov/study/NCT07094204,2. Multi-RAS + Colon,RECRUITING
NCT02102789,A Study of Systemic Chemotherapy With/Without HAI in Patients With Initially Unresectable Colorectal Liver Metastasis,https://clinicaltrials.gov/study/NCT02102789,2. RAS + Colon,RECRUITING
NCT02579278,Circulating Tumour DNA (ctDNA) in Patients With Colorectal Cancer and the Relationship to Imaging Features of Extramural Venous Invasion,https://clinicaltrials.gov/study/NCT02579278,2. RAS + Colon,RECRUITING
NCT02885753,Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver,https://clinicaltrials.gov/study/NCT02885753,2. RAS + Colon,RECRUITING
NCT02986516,Sacral Chordoma: Surgery Versus Definitive Radiation Therapy in Primary Localized Disease,https://clinicaltrials.gov/study/NCT02986516,2. RAS + Colon,RECRUITING
NCT03127111,Genetic and Epigenetic Determinants of Response to Fluorouracil-based Adjuvant Chemotherapy in Patients With Stage III Colorectal Cancer,https://clinicaltrials.gov/study/NCT03127111,2. RAS + Colon,NOT_YET_RECRUITING
NCT03175224,APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors,https://clinicaltrials.gov/study/NCT03175224,2. RAS + Colon,RECRUITING
NCT03190941,Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients,https://clinicaltrials.gov/study/NCT03190941,2. RAS + Colon,RECRUITING
NCT03391934,Comparing Efficacy and Safety of Cetuximab (CinnaGen) Versus Erbitux® (Merck) in Metastatic Colorectal Cancer,https://clinicaltrials.gov/study/NCT03391934,2. RAS + Colon,RECRUITING
NCT03452774,SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry,https://clinicaltrials.gov/study/NCT03452774,2. RAS + Colon,RECRUITING
NCT03526835,A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors,https://clinicaltrials.gov/study/NCT03526835,2. RAS + Colon,RECRUITING
NCT03539822,Cabozantinib Plus Durvalumab with or Without Tremelimumab in Patients with Gastroesophageal Cancer and Other Gastrointestinal Malignancies,https://clinicaltrials.gov/study/NCT03539822,2. RAS + Colon,RECRUITING
NCT03608631,iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation,https://clinicaltrials.gov/study/NCT03608631,2. G12D general,RECRUITING
NCT03714490,MRI Simulation-guided Boost in Short-course Preoperative Radiotherapy for Unresectable Rectal Cancer,https://clinicaltrials.gov/study/NCT03714490,2. RAS + Colon,RECRUITING
NCT03819803,Fecal Microbiota Transplantation in aGvHD After ASCT,https://clinicaltrials.gov/study/NCT03819803,2. RAS + Colon,RECRUITING
NCT03874026,Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients,https://clinicaltrials.gov/study/NCT03874026,2. RAS + Colon,RECRUITING
NCT03919292,"Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca",https://clinicaltrials.gov/study/NCT03919292,2. RAS + Colon,RECRUITING
NCT03923335,The Predictive Value of Guangzhou Panel for Recurrence in Early-stage Colorectal Cancer,https://clinicaltrials.gov/study/NCT03923335,2. RAS + Colon,NOT_YET_RECRUITING
NCT04008797,A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor,https://clinicaltrials.gov/study/NCT04008797,2. RAS + Colon,RECRUITING
NCT04025541,Analysis of Circulating Tumor Markers in Blood,https://clinicaltrials.gov/study/NCT04025541,2. RAS + Colon,RECRUITING
NCT04034173,Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation,https://clinicaltrials.gov/study/NCT04034173,2. RAS + Colon,NOT_YET_RECRUITING
NCT04050345,Tracking Mutations in Cell Free Tumour DNA to Predict Relapse in Early Colorectal Cancer,https://clinicaltrials.gov/study/NCT04050345,2. RAS + Colon,RECRUITING
NCT04204837,Nivolumab for Treatment of Squamous Cell Carcinoma of the Skin,https://clinicaltrials.gov/study/NCT04204837,2. RAS + Colon,RECRUITING
NCT04235114,Evaluation of 89Zr-DFO-nimotuzumab for Non-invasive Imaging of EGFR+ Cancers by Positron Emission Tomography (PET),https://clinicaltrials.gov/study/NCT04235114,2. RAS + Colon,RECRUITING
NCT04485013,TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers,https://clinicaltrials.gov/study/NCT04485013,2. RAS + Colon,RECRUITING
NCT04511039,Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer,https://clinicaltrials.gov/study/NCT04511039,2. RAS + Colon,RECRUITING
NCT04585750,The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE),https://clinicaltrials.gov/study/NCT04585750,2. RAS + Colon,RECRUITING
NCT04678583,Anatomical Resection of Liver MetAstases iN patIents With RAS-mutated Colorectal Cancer,https://clinicaltrials.gov/study/NCT04678583,2. RAS + Colon,RECRUITING
NCT04678648,A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies,https://clinicaltrials.gov/study/NCT04678648,2. RAS + Colon,RECRUITING
NCT04687631,Conversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases,https://clinicaltrials.gov/study/NCT04687631,2. RAS + Colon,RECRUITING
NCT04704661,"Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial",https://clinicaltrials.gov/study/NCT04704661,2. RAS + Colon,RECRUITING
NCT04776655,Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB,https://clinicaltrials.gov/study/NCT04776655,2. RAS + Colon,RECRUITING
NCT04781270,mFOLFOXIRI+Bev vs. mFOLFOX6+Bev for RAS Mutant Unresectable Colorectal Liver-limited Metastases,https://clinicaltrials.gov/study/NCT04781270,2. RAS + Colon,RECRUITING
NCT04831528,"Decision-making of ctDNA in Patients With mCRC After Failure of First-line Treatment Containing Cetuximab - a Single-center, Phase II Clinical Study",https://clinicaltrials.gov/study/NCT04831528,2. RAS + Colon,NOT_YET_RECRUITING
NCT04832776,FOLFOXIRI Plus Cetuximab Versus FOLFOXIRI Plus Bevacizumab in Conversion Therapy of Right-sided Colon Cancer Liver Metastases,https://clinicaltrials.gov/study/NCT04832776,2. RAS + Colon,RECRUITING
NCT04854213,PRELUDE-1 (Prospective Evaluation of Radiotherapy-induced Biologic Effects in Colorectal Cancer Oligometastatic Patients with LUng-limited Disease: Evolution of Cancer Genetics and Regulatory Immune Cells),https://clinicaltrials.gov/study/NCT04854213,2. RAS + Colon,RECRUITING
NCT04888936,"Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies",https://clinicaltrials.gov/study/NCT04888936,2. RAS + Colon,RECRUITING
NCT04923620,Neoadjuvant Cetuximab + Chemotherapy Combined With Short-course Radiotherapy,https://clinicaltrials.gov/study/NCT04923620,2. RAS + Colon,RECRUITING
NCT04929223,A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC),https://clinicaltrials.gov/study/NCT04929223,2. RAS + Colon,RECRUITING
NCT04938986,Interest of the Immunoscore® as a Post-operative Complementary Tool for the Detection of the Risk of Recurrence in Patients With Nonmetastatic Colorectal Cancer,https://clinicaltrials.gov/study/NCT04938986,2. RAS + Colon,RECRUITING
NCT04956640,Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C),https://clinicaltrials.gov/study/NCT04956640,2. RAS + Colon,RECRUITING
NCT04976153,Skeletal Muscle-derived Cell Implantation for Treatment of Fecal Incontinence,https://clinicaltrials.gov/study/NCT04976153,2. RAS + Colon,RECRUITING
NCT04999761,AB122 Platform Study,https://clinicaltrials.gov/study/NCT04999761,2. RAS + Colon,RECRUITING
NCT05007132,Trifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer,https://clinicaltrials.gov/study/NCT05007132,2. RAS + Colon,RECRUITING
NCT05013216,Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer,https://clinicaltrials.gov/study/NCT05013216,2. RAS + Colon,RECRUITING
NCT05022030,First-line mCapOX+Cetuximab vs. mFOLFOX6+Cetuximab for Metastatic Left-sided CRC With Wild-type RAS/BRAF Genes,https://clinicaltrials.gov/study/NCT05022030,2. RAS + Colon,RECRUITING
NCT05062889,Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients,https://clinicaltrials.gov/study/NCT05062889,2. RAS + Colon,RECRUITING
NCT05067283,A Study of MK-1084 in KRAS Mutant Advanced Solid Tumors (MK-1084-001),https://clinicaltrials.gov/study/NCT05067283,2. RAS + Colon,RECRUITING
NCT05101070,S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors,https://clinicaltrials.gov/study/NCT05101070,2. RAS + Colon,RECRUITING
NCT05107674,A Study of NX-1607 in Adults With Advanced Malignancies,https://clinicaltrials.gov/study/NCT05107674,2. RAS + Colon,RECRUITING
NCT05111860,Neoadjuvant Bevacizumab + Chemotherapy Combined With Short-course Radiotherapy,https://clinicaltrials.gov/study/NCT05111860,2. RAS + Colon,RECRUITING
NCT05118854,A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation,https://clinicaltrials.gov/study/NCT05118854,2. RAS + Colon,RECRUITING
NCT05171075,A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE,https://clinicaltrials.gov/study/NCT05171075,2. RAS + Colon,RECRUITING
NCT05171660,Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer,https://clinicaltrials.gov/study/NCT05171660,2. RAS + Colon,RECRUITING
NCT05176665,EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers,https://clinicaltrials.gov/study/NCT05176665,2. RAS + Colon,RECRUITING
NCT05186116,LDLT in Non Resectable Colo-rectal Cancer Liver Metastasis,https://clinicaltrials.gov/study/NCT05186116,2. RAS + Colon,RECRUITING
NCT05200442,A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer,https://clinicaltrials.gov/study/NCT05200442,2. RAS + Colon,RECRUITING
NCT05229003,Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRC,https://clinicaltrials.gov/study/NCT05229003,2. RAS + Colon,RECRUITING
NCT05239650,Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07+HLX10 +mFOLFOX6 or HLX07 Monotherapy in Patients With mCRC,https://clinicaltrials.gov/study/NCT05239650,2. RAS + Colon,NOT_YET_RECRUITING
NCT05239741,Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66),https://clinicaltrials.gov/study/NCT05239741,2. RAS + Colon,RECRUITING
NCT05253651,A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer,https://clinicaltrials.gov/study/NCT05253651,2. RAS + Colon,RECRUITING
NCT05288205,Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation,https://clinicaltrials.gov/study/NCT05288205,2. RAS + Colon,RECRUITING
NCT05291156,CAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge Strategy,https://clinicaltrials.gov/study/NCT05291156,2. RAS + Colon,RECRUITING
NCT05299840,Impact of Using the Oncogramme® Device to Select the First Line of Treatment for Patients With Metastatic Colorectal Cancer,https://clinicaltrials.gov/study/NCT05299840,2. RAS + Colon,RECRUITING
NCT05310643,Nivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRC,https://clinicaltrials.gov/study/NCT05310643,2. RAS + Colon,RECRUITING
NCT05354674,Multimodal Deep Learning Signature for Evaluation of Response to Bevacizumab in Patient With Colorectal Cancer Liver Metastasis,https://clinicaltrials.gov/study/NCT05354674,2. RAS + Colon,NOT_YET_RECRUITING
NCT05359393,A Combination Therapy Including Anti-PD-1 Immunotherapy in MSS Rectal Cancer With Resectable Distal Metastasis,https://clinicaltrials.gov/study/NCT05359393,2. RAS + Colon,NOT_YET_RECRUITING
NCT05379595,A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer,https://clinicaltrials.gov/study/NCT05379595,2. RAS + Colon,RECRUITING
NCT05451056,"An Open-label, Phase 2trial of Sotorasib in KRAS G12C-mutant Non-small-cell Lung Cancer(NSCLC) Patients and a Translational Study to Find Acquired Resistance Mechanism to Sotorasib",https://clinicaltrials.gov/study/NCT05451056,2. RAS + Colon,NOT_YET_RECRUITING
NCT05462613,Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer,https://clinicaltrials.gov/study/NCT05462613,2. RAS + Colon,RECRUITING
NCT05522738,Safety and Efficacy of Fruquintinib+FOLFIRI in RAS-mutated Metastatic Colorectal Cancer,https://clinicaltrials.gov/study/NCT05522738,2. RAS + Colon,RECRUITING
NCT05592626,"A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors",https://clinicaltrials.gov/study/NCT05592626,2. RAS + Colon,RECRUITING
NCT05631041,Effect of Silymarin in Metastatic Colorectal Cancer Patients,https://clinicaltrials.gov/study/NCT05631041,2. RAS + Colon,RECRUITING
NCT05634590,The Efficacy and Safety of Fruquintinib Plus FOLFIRI/FOLFOX as Second-line Treatment in Patients With RAS-mutant Metastatic Colorectal Cancer,https://clinicaltrials.gov/study/NCT05634590,2. RAS + Colon,NOT_YET_RECRUITING
NCT05638295,Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial),https://clinicaltrials.gov/study/NCT05638295,2. RAS + Colon,RECRUITING
NCT05640726,The First-line Treatment of RCLM With RAS Mutation Was Local Short-course Radiotherapy (SCRT) + PD-1+ Standard Therapy,https://clinicaltrials.gov/study/NCT05640726,2. RAS + Colon,NOT_YET_RECRUITING
NCT05651022,Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors,https://clinicaltrials.gov/study/NCT05651022,2. RAS + Colon,RECRUITING
NCT05672524,A Study of Tucatinib and Trastuzumab in People With Rectal Cancer,https://clinicaltrials.gov/study/NCT05672524,2. RAS + Colon,RECRUITING
NCT05673512,To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Metastatic Colorectal Cancer,https://clinicaltrials.gov/study/NCT05673512,2. RAS + Colon,RECRUITING
NCT05694936,Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer,https://clinicaltrials.gov/study/NCT05694936,2. RAS + Colon,RECRUITING
NCT05706779,Encorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cancer,https://clinicaltrials.gov/study/NCT05706779,2. RAS + Colon,RECRUITING
NCT05725200,Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer,https://clinicaltrials.gov/study/NCT05725200,2. RAS + Colon,RECRUITING
NCT05727163,FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients,https://clinicaltrials.gov/study/NCT05727163,2. RAS + Colon,RECRUITING
NCT05742425,Serplulimab Combined With FOLFIRI and Bevacizumab in the Treatment of Colon Cancer Peritoneal Metastases,https://clinicaltrials.gov/study/NCT05742425,2. RAS + Colon,RECRUITING
NCT05759728,"A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer",https://clinicaltrials.gov/study/NCT05759728,2. RAS + Colon,RECRUITING
NCT05771181,Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients,https://clinicaltrials.gov/study/NCT05771181,2. RAS + Colon,RECRUITING
NCT05806931,Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer,https://clinicaltrials.gov/study/NCT05806931,2. RAS + Colon,RECRUITING
NCT05845450,Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN),https://clinicaltrials.gov/study/NCT05845450,2. RAS + Colon,RECRUITING
NCT05848739,A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors,https://clinicaltrials.gov/study/NCT05848739,2. RAS + Colon,RECRUITING
NCT05876806,Dabrafenib Plus Trametinib in Patients With Advanced Solid Tumor Having BRAF V600E Mutation or Clinically Actionable BRAF Gene Alterations,https://clinicaltrials.gov/study/NCT05876806,2. RAS + Colon,RECRUITING
NCT05881746,Anatomical Resection VS. Nonanatomical Resection for Colorectal Liver Metastases With Gene Mutation or Right-sidedness,https://clinicaltrials.gov/study/NCT05881746,2. RAS + Colon,NOT_YET_RECRUITING
NCT05928312,Fruquintinib Combined With Chemotherapy as Third-line /Third-line+ Treatment in Advanced Colorectal Cancer,https://clinicaltrials.gov/study/NCT05928312,2. RAS + Colon,NOT_YET_RECRUITING
NCT05933980,"Toripalimab,Celecoxib and Regorafenib in the Treatment of Refractory Advanced Colorectal Cancer",https://clinicaltrials.gov/study/NCT05933980,2. RAS + Colon,RECRUITING
NCT05948072,Cetuximab+mFOLFOX6 VS. mFOLFOX6 Alone in RAS/BRAF Wild Type Patients With High-Risk Resectable CRLM,https://clinicaltrials.gov/study/NCT05948072,2. RAS + Colon,NOT_YET_RECRUITING
NCT05954429,"A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-isolated Hepatic Metastatic Colorectal Cancer: a Single-center, Phase 2 Study",https://clinicaltrials.gov/study/NCT05954429,2. RAS + Colon,NOT_YET_RECRUITING
NCT05959356,"Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal Cancer",https://clinicaltrials.gov/study/NCT05959356,2. RAS + Colon,RECRUITING
NCT05962502,Cetuximab Plus Irinotecan in Patients With NeoRAS Wild-type Metastatic Colorectal Cancer In Third-line Therapy,https://clinicaltrials.gov/study/NCT05962502,2. RAS + Colon,RECRUITING
NCT05970302,XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC,https://clinicaltrials.gov/study/NCT05970302,2. RAS + Colon,RECRUITING
NCT05970705,Regorafenib Combined With TAS-102 Versus Regorafenib Monotherapy in Third or Later Line Therapy of mCRC,https://clinicaltrials.gov/study/NCT05970705,2. RAS + Colon,RECRUITING
NCT05983159,A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations,https://clinicaltrials.gov/study/NCT05983159,2. G12D general,RECRUITING
NCT05985707,KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma,https://clinicaltrials.gov/study/NCT05985707,2. RAS + Colon,NOT_YET_RECRUITING
NCT05985954,Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy,https://clinicaltrials.gov/study/NCT05985954,2. RAS + Colon,RECRUITING
NCT05991102,Amplitude Modulated Radiofrequency Electromagnetic Field Treatment Combined With TAS-102 (Lonsurf) and Bevacizumab in Refractory Metastatic Colorectal Cancer,https://clinicaltrials.gov/study/NCT05991102,2. RAS + Colon,RECRUITING
NCT05999396,"FIH, Bispecific CD276xCD3 Antibody CC-3 in Patients With Colorectal Cancer",https://clinicaltrials.gov/study/NCT05999396,2. RAS + Colon,RECRUITING
NCT06008288,A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.,https://clinicaltrials.gov/study/NCT06008288,2. RAS + Colon,RECRUITING
NCT06010888,Fruquintinib With mFOLFOX6/FOLFIRI as First-Line Therapy for Conversion Surgery in mCRC,https://clinicaltrials.gov/study/NCT06010888,2. RAS + Colon,RECRUITING
NCT06015724,Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer,https://clinicaltrials.gov/study/NCT06015724,2. RAS + Colon,RECRUITING
NCT06026410,KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors,https://clinicaltrials.gov/study/NCT06026410,2. RAS + Colon,RECRUITING
NCT06078800,A Study of YL-17231 in Patients With Advanced Solid Tumors,https://clinicaltrials.gov/study/NCT06078800,2. RAS + Colon,RECRUITING
NCT06096974,"Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS",https://clinicaltrials.gov/study/NCT06096974,2. RAS + Colon,RECRUITING
NCT06128551,Study of RMC-6291 in Combination with RMC-6236 in Participants with Advanced KRAS G12C Mutant Solid Tumors,https://clinicaltrials.gov/study/NCT06128551,2. RAS + Colon,RECRUITING
NCT06131840,A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors,https://clinicaltrials.gov/study/NCT06131840,2. RAS + Colon,RECRUITING
NCT06149481,"Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)",https://clinicaltrials.gov/study/NCT06149481,2. RAS + Colon,RECRUITING
NCT06162221,Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC,https://clinicaltrials.gov/study/NCT06162221,2. G12D general,RECRUITING
NCT06166836,a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors,https://clinicaltrials.gov/study/NCT06166836,2. RAS + Colon,RECRUITING
NCT06169202,A Study of Fruquintinib in Combination With Irinotecan and Capecitabine for the Second-line Treatment of Patients,https://clinicaltrials.gov/study/NCT06169202,2. RAS + Colon,RECRUITING
NCT06176885,Efficacy and Safety of Combined With Immunotherapy After Induction Therapy With Chemotherapy and Targeted Therapy in the First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer,https://clinicaltrials.gov/study/NCT06176885,2. RAS + Colon,RECRUITING
NCT06192680,Liposomal Irinotecan and Capecitabine Plus Bevacizumab as Second-line Therapy in Metastatic Colorectal Cancer,https://clinicaltrials.gov/study/NCT06192680,2. RAS + Colon,NOT_YET_RECRUITING
NCT06194929,"Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma",https://clinicaltrials.gov/study/NCT06194929,2. RAS + Colon,RECRUITING
NCT06206096,PD-1 Antibody Plus Bevacizumab and CAPOX as First-line Treatment for RAS-mut MSS mCRC,https://clinicaltrials.gov/study/NCT06206096,2. RAS + Colon,RECRUITING
NCT06207656,Study to Evaluate the Efficacy and Safety of Cetuximab in Combination with Encorafenib Plus Binimetinib As Induction Treatment in BRAF V600E Mutated MSS Initially Resectable or Potentially Resectable Advanced Colorectal Cancer,https://clinicaltrials.gov/study/NCT06207656,2. RAS + Colon,RECRUITING
NCT06218810,"Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancer",https://clinicaltrials.gov/study/NCT06218810,2. RAS + Colon,RECRUITING
NCT06226857,Other Oncogene Mutations for Anti-EGFR Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal Cancer,https://clinicaltrials.gov/study/NCT06226857,2. RAS + Colon,RECRUITING
NCT06229340,Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations,https://clinicaltrials.gov/study/NCT06229340,2. RAS + Colon,RECRUITING
NCT06231017,Adebrelimab Plus Cetuximab and Chemotherapy for Patients With RAS/BRAF Wild-Type Unresectable Liver Metastases Colorectal Cancer,https://clinicaltrials.gov/study/NCT06231017,2. RAS + Colon,RECRUITING
NCT06239623,ERK Inhibitor JSI-1187 in Advanced Solid Tumors,https://clinicaltrials.gov/study/NCT06239623,2. RAS + Colon,RECRUITING
NCT06242067,Second-line Treatment of Metastatic Colorectal Cancer,https://clinicaltrials.gov/study/NCT06242067,2. RAS + Colon,RECRUITING
NCT06244771,A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors,https://clinicaltrials.gov/study/NCT06244771,2. RAS + Colon,RECRUITING
NCT06252649,"Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation",https://clinicaltrials.gov/study/NCT06252649,2. RAS + Colon,RECRUITING
NCT06279351,Thalidomide Enhances Clinical Efficacy of Cetuximab Combined With Standard Chemotherapy for Left Colorectal Cancer,https://clinicaltrials.gov/study/NCT06279351,2. RAS + Colon,RECRUITING
NCT06280495,"Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients",https://clinicaltrials.gov/study/NCT06280495,2. RAS + Colon,RECRUITING
NCT06282445,Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer,https://clinicaltrials.gov/study/NCT06282445,2. RAS + Colon,RECRUITING
NCT06301386,Everolimus Combined With PD-1 in Advanced Colorectal Cancer Patients,https://clinicaltrials.gov/study/NCT06301386,2. RAS + Colon,NOT_YET_RECRUITING
NCT06321081,ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC,https://clinicaltrials.gov/study/NCT06321081,2. RAS + Colon,RECRUITING
NCT06322147,Chemotherapy With Cetuximab as Conversion Therapy in RAS/BRAF WT Unresectable Liver Metastasis Right-sided Colon Cancer,https://clinicaltrials.gov/study/NCT06322147,2. RAS + Colon,RECRUITING
NCT06322563,Combination of LTC004 and Regorafenib to Treat Patients With Advanced/Metastatic CRC,https://clinicaltrials.gov/study/NCT06322563,2. RAS + Colon,NOT_YET_RECRUITING
NCT06328439,A Study to Evaluate ANS014004 in Subjects With Locally Advanced or Metastatic Solid Tumors,https://clinicaltrials.gov/study/NCT06328439,2. RAS + Colon,RECRUITING
NCT06332079,Holmium-166 TARE in Liver Limited Unresectable Colorectal Cancer Patients,https://clinicaltrials.gov/study/NCT06332079,2. RAS + Colon,RECRUITING
NCT06336902,Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorectal Cancer,https://clinicaltrials.gov/study/NCT06336902,2. RAS + Colon,RECRUITING
NCT06341296,Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal Cancer,https://clinicaltrials.gov/study/NCT06341296,2. RAS + Colon,RECRUITING
NCT06343116,Nimotuzumab Combined With Trifluridine/Tipiracil in the Treatment of Refractory Metastatic Colorectal Cancer,https://clinicaltrials.gov/study/NCT06343116,2. RAS + Colon,NOT_YET_RECRUITING
NCT06368141,Neoadjuvant Chemotherapy Plus Sequential Immune Checkpoint Inhibitor (ICI) Therapy in Locally Advanced Colon Cancer,https://clinicaltrials.gov/study/NCT06368141,2. RAS + Colon,RECRUITING
NCT06369259,"Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer",https://clinicaltrials.gov/study/NCT06369259,2. RAS + Colon,RECRUITING
NCT06379399,Trifluridine/Tipiracil Combined With Cetuximab in the Treatment of Third-line and Above RAS/BRAF Wild-type mCRC,https://clinicaltrials.gov/study/NCT06379399,2. RAS + Colon,RECRUITING
NCT06384235,Phase II Clinical Study of LTC004 in Patients With mCRC,https://clinicaltrials.gov/study/NCT06384235,2. RAS + Colon,NOT_YET_RECRUITING
NCT06399757,A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors,https://clinicaltrials.gov/study/NCT06399757,2. RAS + Colon,RECRUITING
NCT06411600,Combination Therapy for BRAF-V600E Metastatic CRCm,https://clinicaltrials.gov/study/NCT06411600,2. RAS + Colon,RECRUITING
NCT06411691,KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer,https://clinicaltrials.gov/study/NCT06411691,2. RAS + Colon,RECRUITING
NCT06412198,"A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations",https://clinicaltrials.gov/study/NCT06412198,2. RAS + Colon,RECRUITING
NCT06425133,Regorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal Cancers,https://clinicaltrials.gov/study/NCT06425133,2. RAS + Colon,RECRUITING
NCT06434090,Liposomal Irinotecan Plus Bevacizumab in Irinotecan-refractory Metastatic Colorectal Cancer,https://clinicaltrials.gov/study/NCT06434090,2. RAS + Colon,NOT_YET_RECRUITING
NCT06440902,Exploration of Therapeutic Strategies for NeoRAS Wild-type Metastatic Colorectal Cancer Based on Circulating Tumor DNA,https://clinicaltrials.gov/study/NCT06440902,2. RAS + Colon,RECRUITING
NCT06441565,Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer,https://clinicaltrials.gov/study/NCT06441565,2. RAS + Colon,RECRUITING
NCT06446557,De-scalation or swItch of Treatment According to Circulating tuMOr DNA Variation After 2 Cycles of Doublet Chemotherapy Plus Targeted Agent in Metastatic Unresectable Colorectal Cancer,https://clinicaltrials.gov/study/NCT06446557,2. RAS + Colon,NOT_YET_RECRUITING
NCT06447727,Efficacy and Safety of 90Y Microsphere Combined With FOLFIRI and Bevacizumab in Second-line Treatment of CRLM,https://clinicaltrials.gov/study/NCT06447727,2. RAS + Colon,RECRUITING
NCT06449989,Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Colorectal Cancer,https://clinicaltrials.gov/study/NCT06449989,2. RAS + Colon,RECRUITING
NCT06455254,Cadonilimab Combined With Regorafenib as A Third-line Treatment in Patients With MSS CRLM,https://clinicaltrials.gov/study/NCT06455254,2. RAS + Colon,RECRUITING
NCT06462183,Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC),https://clinicaltrials.gov/study/NCT06462183,2. RAS + Colon,RECRUITING
NCT06478251,T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor,https://clinicaltrials.gov/study/NCT06478251,2. G12D general,RECRUITING
NCT06484556,T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor,https://clinicaltrials.gov/study/NCT06484556,2. G12D general,RECRUITING
NCT06484790,T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor,https://clinicaltrials.gov/study/NCT06484790,2. G12D general,RECRUITING
NCT06490913,Chemotherapy Plus EGFR Monoclonal Antibody in Patients With Liver Metastases From Colorectal Cancer With ctDNA Superselective Negative Genes,https://clinicaltrials.gov/study/NCT06490913,2. RAS + Colon,NOT_YET_RECRUITING
NCT06495463,Lonsurf® (Trifluridine/Tipiracil) Plus Chemotherapy in Metastatic Colorectal Cancer Prospective Study in Taiwan,https://clinicaltrials.gov/study/NCT06495463,2. RAS + Colon,RECRUITING
NCT06497985,A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients,https://clinicaltrials.gov/study/NCT06497985,2. RAS + Colon,RECRUITING
NCT06500676,A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations,https://clinicaltrials.gov/study/NCT06500676,2. G12D general,RECRUITING
NCT06509126,Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer,https://clinicaltrials.gov/study/NCT06509126,2. RAS + Colon,RECRUITING
NCT06512480,"Colorectal Surgery, a New Robotic Platform (Hugo Ras)",https://clinicaltrials.gov/study/NCT06512480,2. RAS + Colon,RECRUITING
NCT06520488,A Study of HRS-4642 in Combination With Antineoplastic Agents in Advanced Solid Tumors,https://clinicaltrials.gov/study/NCT06520488,2. G12D general,RECRUITING
NCT06521866,"Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer",https://clinicaltrials.gov/study/NCT06521866,2. RAS + Colon,RECRUITING
NCT06522919,Sequential Immunochemotherapy Treatment with Pembrolizumab Plus Dendritic Cell (DC) Vaccine Followed by Trifluridine/Tipiracil Plus Bevacizumab in Refractory Mismatch-repair-proficient (pMMR) or Microsatellite-stable (MSS) Metastatic Colorectal Cancer,https://clinicaltrials.gov/study/NCT06522919,2. RAS + Colon,RECRUITING
NCT06542588,"Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy, HLX07and Serplulimab in LARC",https://clinicaltrials.gov/study/NCT06542588,2. RAS + Colon,RECRUITING
NCT06543836,ctDNA-guided Treatment of TKI Plus PD-1 Inhibitor for Advanced pMMR/MSS Colorectal Cancer,https://clinicaltrials.gov/study/NCT06543836,2. RAS + Colon,RECRUITING
NCT06546150,RE002 T Cell Injection for the Treatment of KRAS G12D Mutated Solid Tumors,https://clinicaltrials.gov/study/NCT06546150,2. G12D general,NOT_YET_RECRUITING
NCT06547203,"Cetuximab, Irinotecan, Toripalimab in RAS/BRAF Wild-type Ultraselected Right-sided Colorectal Cancer Study",https://clinicaltrials.gov/study/NCT06547203,2. RAS + Colon,RECRUITING
NCT06550453,"Safety and Efficacy of Pembrolizumab in Combination with Bevacizumab + CapeOX in the Neoadjuvant Treatment of RAS-mutated, BRAF Wild-type, Microsatellite-stabilized, Locally Advanced Colorectal Cancer",https://clinicaltrials.gov/study/NCT06550453,2. RAS + Colon,RECRUITING
NCT06553885,Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC,https://clinicaltrials.gov/study/NCT06553885,2. RAS + Colon,RECRUITING
NCT06562543,"A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer",https://clinicaltrials.gov/study/NCT06562543,2. RAS + Colon,RECRUITING
NCT06566755,Cadonilimab (AK104) Combined With Chemotherapy and Bevacizumab as First-line Treatment for RAS Mutated or Right Sided-metastatic MSS Colorectal Cancer,https://clinicaltrials.gov/study/NCT06566755,2. RAS + Colon,RECRUITING
NCT06578559,Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC,https://clinicaltrials.gov/study/NCT06578559,2. RAS + Colon,RECRUITING
NCT06585488,"A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification",https://clinicaltrials.gov/study/NCT06585488,2. RAS + Colon,RECRUITING
NCT06589830,TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer,https://clinicaltrials.gov/study/NCT06589830,2. RAS + Colon,NOT_YET_RECRUITING
NCT06593548,Lvosidenib (AK112) Combined With CapeOX and Radiotherapy in Patients With Unresectable Metastatic MSS-type Colorectal Cancer,https://clinicaltrials.gov/study/NCT06593548,2. RAS + Colon,NOT_YET_RECRUITING
NCT06603818,Immunotherapies in Combination With Stereotactic Body Radiation Radiotherapy in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC),https://clinicaltrials.gov/study/NCT06603818,2. RAS + Colon,RECRUITING
NCT06607458,Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease,https://clinicaltrials.gov/study/NCT06607458,2. RAS + Colon,RECRUITING
NCT06616259,"First-line Treatment of MCapOX + Cetuximab Vs. MFOLFOX6 + Cetuximab for RAS/BRAF Wild-type, MSS, Unresectable Left-Sided MCRC: a Multicenter, Randomized, Controlled, Phase III Study",https://clinicaltrials.gov/study/NCT06616259,2. RAS + Colon,NOT_YET_RECRUITING
NCT06619587,"A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors",https://clinicaltrials.gov/study/NCT06619587,2. G12D general,RECRUITING
NCT06634875,Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS),https://clinicaltrials.gov/study/NCT06634875,2. RAS + Colon,RECRUITING
NCT06645236,DHF-20-1839-2: Clinical Performance Study Protocol for Therascreen® KRAS RGQ PCR Kit,https://clinicaltrials.gov/study/NCT06645236,2. RAS + Colon,RECRUITING
NCT06654037,"Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal Cancer",https://clinicaltrials.gov/study/NCT06654037,2. RAS + Colon,RECRUITING
NCT06654219,Protective Benefits of a Clear Liquid Diet on Residual Gastric Content in Patients Taking Glucagon Like Peptide-1 Receptor (GLP-1 RA) Agonist Prior to Anesthesia,https://clinicaltrials.gov/study/NCT06654219,2. RAS + Colon,RECRUITING
NCT06657144,A Study of CHS-114 in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors,https://clinicaltrials.gov/study/NCT06657144,2. RAS + Colon,RECRUITING
NCT06662786,A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer,https://clinicaltrials.gov/study/NCT06662786,2. RAS + Colon,RECRUITING
NCT06678919,AGMT Metastatic Colorectal Cancer Registry (mCRC) Third Line and Beyond,https://clinicaltrials.gov/study/NCT06678919,2. RAS + Colon,RECRUITING
NCT06695845,A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors,https://clinicaltrials.gov/study/NCT06695845,2. RAS + Colon,RECRUITING
NCT06699836,A Phase 2 Study of Leronlimab in Combination With TAS-102 + Bevacizumab in Previously Treated Participants With mCRC,https://clinicaltrials.gov/study/NCT06699836,2. RAS + Colon,RECRUITING
NCT06714357,ValproIc Acid to Potentiate Anti-EGFR Treatment Efficacy and Prevent/Revert Resistance in Colorectal Cancer,https://clinicaltrials.gov/study/NCT06714357,2. RAS + Colon,RECRUITING
NCT06720987,A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies,https://clinicaltrials.gov/study/NCT06720987,2. RAS + Colon,RECRUITING
NCT06722183,Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor Entities,https://clinicaltrials.gov/study/NCT06722183,2. RAS + Colon,NOT_YET_RECRUITING
NCT06723236,A Study of MGC028 in Participants With Advanced Solid Tumors,https://clinicaltrials.gov/study/NCT06723236,2. RAS + Colon,RECRUITING
NCT06750094,A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy,https://clinicaltrials.gov/study/NCT06750094,2. RAS + Colon,RECRUITING
NCT06753721,"An Open-label, Multicenter, Single-arm Clinical Study on the Use of Doxorubicin Liposome in Combination With CapOX and Bevacizumab Regimen for First-line Treatment of Advanced Colorectal Adenocarcinoma With SMAD4R361H/C Mutation.",https://clinicaltrials.gov/study/NCT06753721,2. RAS + Colon,NOT_YET_RECRUITING
NCT06760702,"A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AUR 109 in Patients with Colorectal, Ovarian, and Renal Cancers",https://clinicaltrials.gov/study/NCT06760702,2. RAS + Colon,RECRUITING
NCT06763029,Irinotecan Liposomes Combined with Cetuximab + Vermofenib in First-line Failure of Advanced Colorectal Cancer,https://clinicaltrials.gov/study/NCT06763029,2. RAS + Colon,RECRUITING
NCT06764771,A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors,https://clinicaltrials.gov/study/NCT06764771,2. RAS + Colon,RECRUITING
NCT06767046,KRAS-Specific Autologous TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors,https://clinicaltrials.gov/study/NCT06767046,2. RAS + Colon,NOT_YET_RECRUITING
NCT06770452,HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients,https://clinicaltrials.gov/study/NCT06770452,2. G12D general,RECRUITING
NCT06771622,Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors,https://clinicaltrials.gov/study/NCT06771622,2. RAS + Colon,RECRUITING
NCT06776757,Sintilimab in Combination with Cetuximab and Chemotherapy As First-line Treatment for RAS/BRAF Wild-type Advanced Colorectal Cancer,https://clinicaltrials.gov/study/NCT06776757,2. RAS + Colon,RECRUITING
NCT06781398,Robotic Surgery in the Treatment of Deep Endometriosis: Da Vinci Vs HUGO RAS Comparison,https://clinicaltrials.gov/study/NCT06781398,2. RAS + Colon,NOT_YET_RECRUITING
NCT06783569,A First-in-Human Escalation and Expansion Study of Patients With Advanced Solid Tumors,https://clinicaltrials.gov/study/NCT06783569,2. RAS + Colon,RECRUITING
NCT06787105,Fruquintinib in Patients With Metastatic Colorectal Cancer,https://clinicaltrials.gov/study/NCT06787105,2. RAS + Colon,RECRUITING
NCT06789172,"A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors",https://clinicaltrials.gov/study/NCT06789172,2. RAS + Colon,RECRUITING
NCT06797336,A Study of PT0253 in Participants With KRAS G12D Mutated Advanced Solid Tumors,https://clinicaltrials.gov/study/NCT06797336,2. G12D general,RECRUITING
NCT06801665,FMT+ QL1706+Bevacizumab+ XELOX as First-line Treatment for Advanced MSS-type Colon Cancer With Liver Metastasis,https://clinicaltrials.gov/study/NCT06801665,2. RAS + Colon,NOT_YET_RECRUITING
NCT06804824,A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors,https://clinicaltrials.gov/study/NCT06804824,2. RAS + Colon,RECRUITING
NCT06807619,A Study of Sotorasib in People With Brain Tumors,https://clinicaltrials.gov/study/NCT06807619,2. RAS + Colon,RECRUITING
NCT06835179,"SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer.",https://clinicaltrials.gov/study/NCT06835179,2. RAS + Colon,NOT_YET_RECRUITING
NCT06835569,A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations,https://clinicaltrials.gov/study/NCT06835569,2. RAS + Colon,RECRUITING
NCT06838338,JAB-21822 Combined With Chemotherapy in Second-line KRAS G12C CRC,https://clinicaltrials.gov/study/NCT06838338,2. RAS + Colon,RECRUITING
NCT06855849,"An Open-label, Single-arm, Multicenter Phase II Study to Evaluate the Efficacy of Amivantamab in Combination With FOLFIRI as a Second-line Treatment in Patients With RAS/BRAF Wild-type Advanced Colorectal Cancer Progressing on Prior Anti-EGFR Based Treatment.",https://clinicaltrials.gov/study/NCT06855849,2. RAS + Colon,NOT_YET_RECRUITING
NCT06856837,- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases,https://clinicaltrials.gov/study/NCT06856837,2. RAS + Colon,RECRUITING
NCT06857773,Induction Treatment for Initially Unresectable Colorectal Liver Metastases: Combined Hepatic Arterial Infusion Pump Therapy With Systemic Therapy,https://clinicaltrials.gov/study/NCT06857773,2. RAS + Colon,RECRUITING
NCT06862115,The Effect of Discontinuation of Renin Angiotensin System Inhibitors on the Perioperative Myocardial Injury in Adult Patients Undergoing Colorectal Cancer Surgery,https://clinicaltrials.gov/study/NCT06862115,2. RAS + Colon,RECRUITING
NCT06876142,Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma,https://clinicaltrials.gov/study/NCT06876142,2. RAS + Colon,RECRUITING
NCT06878131,Precision-MRD: Prospective Observational Study of Biomarker-directed Systemic Therapy for Colorectal Cancer Patients With Minimal Residual Disease,https://clinicaltrials.gov/study/NCT06878131,2. RAS + Colon,RECRUITING
NCT06878612,a Polyphenol Whole Tumor Cell Vaccine in Patients With Advanced Malignant Solid Tumors,https://clinicaltrials.gov/study/NCT06878612,2. RAS + Colon,RECRUITING
NCT06879912,A Study to Understand the Utility of the Force Feedback Instruments in Robotic Procedures Using da Vinci 5 Robot,https://clinicaltrials.gov/study/NCT06879912,2. RAS + Colon,RECRUITING
NCT06882915,"Efficacy and Safety of Trifluridine/tipiracil (TAS-102) Combined with Bevacizumab and Putalimab in the Treatment of Patients with MCRC After Cytoreductive Surgery: a Single-arm, Single-center Clinical Study",https://clinicaltrials.gov/study/NCT06882915,2. RAS + Colon,NOT_YET_RECRUITING
NCT06892054,Sotorasib Combined With First-line Chemotherapy for Advanced Pancreatic Adenocarcinoma,https://clinicaltrials.gov/study/NCT06892054,2. RAS + Colon,NOT_YET_RECRUITING
NCT06895031,Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS,https://clinicaltrials.gov/study/NCT06895031,2. RAS + Colon,RECRUITING
NCT06898385,A Phase I Clinical Study of IX001 TCR-T Injection in the Treatment of Advanced Pancreatic Cancer Patients With KRAS G12V Mutation,https://clinicaltrials.gov/study/NCT06898385,2. RAS + Colon,RECRUITING
NCT06904066,Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies,https://clinicaltrials.gov/study/NCT06904066,2. G12D general,RECRUITING
NCT06908031,SCRT + mFOLFOX6 + PD-1 Antibody + Targeted Therapy for HIgh-Risk pMMR/MSS Rectal Cancer,https://clinicaltrials.gov/study/NCT06908031,2. RAS + Colon,RECRUITING
NCT06922383,A Clinical Study of Arfolitixorin in Patients With mCRC,https://clinicaltrials.gov/study/NCT06922383,2. RAS + Colon,RECRUITING
NCT06933069,Safety and Tolerability of CMAB017 In Patients With Advanced Solid Tumors,https://clinicaltrials.gov/study/NCT06933069,2. RAS + Colon,RECRUITING
NCT06934538,"First-in-human Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer",https://clinicaltrials.gov/study/NCT06934538,2. RAS + Colon,RECRUITING
NCT06949761,"A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of QLC1101 in Combination With Other Therapies in the Treatment of Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation",https://clinicaltrials.gov/study/NCT06949761,2. G12D general,NOT_YET_RECRUITING
NCT06949982,"Efficacy And Safety Of Hydroxychloroquine Combined With Methotrexate, Capecitabine And Bevacizumab Vs. Regorafenib In Participants With Refractory Metastatic Colorectal Cancer With Mutations In RAS Genes",https://clinicaltrials.gov/study/NCT06949982,2. RAS + Colon,RECRUITING
NCT06959550,Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer,https://clinicaltrials.gov/study/NCT06959550,2. RAS + Colon,RECRUITING
NCT06959589,"The Efficacy and Safety of IBI351, Cetuximab β Combined With FOLFIRI as First-line /IBI351, Cetuximab β as Second-line in the Treatment of KRAS G12C-mutated Metastatic Colorectal Cancer",https://clinicaltrials.gov/study/NCT06959589,2. RAS + Colon,NOT_YET_RECRUITING
NCT06959693,"A Clinical Study to Evaluate the Efficacy and Safety of Envafolimab Combined With Cetuxima-βand mFOLFOX6 in Patients With MSS, RAS/BRAF Wild-Type Metastatic Colorectal Cancer (mCRC)",https://clinicaltrials.gov/study/NCT06959693,2. RAS + Colon,NOT_YET_RECRUITING
NCT06963398,A Study of HS-10529 in KRAS G12D Patients With Advanced Solid Tumors,https://clinicaltrials.gov/study/NCT06963398,2. G12D general,NOT_YET_RECRUITING
NCT06963502,A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors,https://clinicaltrials.gov/study/NCT06963502,2. RAS + Colon,NOT_YET_RECRUITING
NCT06973564,JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration,https://clinicaltrials.gov/study/NCT06973564,2. G12D general,RECRUITING
NCT06985316,An Exploratory Clinical Study Evaluating the Efficacy and Safety of Tunlametinib Combined With Fruquintinib in the Third-line Treatment of Advanced Colorectal Cancer Patients With RAS Mutations.,https://clinicaltrials.gov/study/NCT06985316,2. RAS + Colon,NOT_YET_RECRUITING
NCT06992258,A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer,https://clinicaltrials.gov/study/NCT06992258,2. RAS + Colon,NOT_YET_RECRUITING
NCT06992648,Trifluridine/Tipiracil Plus Regorafenib vs Trifluridine/Tipiracil Plus Bevacizumab for Refractory Metastatic Colorectal Cancer,https://clinicaltrials.gov/study/NCT06992648,2. RAS + Colon,RECRUITING
NCT06997497,A Clinical Study of MK-1084 With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012),https://clinicaltrials.gov/study/NCT06997497,2. RAS + Colon,RECRUITING
NCT06998940,"Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations",https://clinicaltrials.gov/study/NCT06998940,2. RAS + Colon,NOT_YET_RECRUITING
NCT06999252,Rimegepant Combined With PD-1 in Liver Metastasis Colorectal Cancer Patients,https://clinicaltrials.gov/study/NCT06999252,2. RAS + Colon,NOT_YET_RECRUITING
NCT07000305,A Study of Cetuximabβ Combined With Envolimab and mFOLFOX6 in Subjects With Advanced Colorectal Cancer,https://clinicaltrials.gov/study/NCT07000305,2. RAS + Colon,NOT_YET_RECRUITING
NCT07001592,Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors,https://clinicaltrials.gov/study/NCT07001592,2. RAS + Colon,RECRUITING
NCT07004244,Application of KRAS Vaccine in the Treatment of KRAS-mutated Malignancies,https://clinicaltrials.gov/study/NCT07004244,2. G12D general,RECRUITING
NCT07004413,Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RAS/BRAF Wild-type mCRC Patients,https://clinicaltrials.gov/study/NCT07004413,2. RAS + Colon,NOT_YET_RECRUITING
NCT07006142,Effect of Prolonged Fasting Time on Gastric Residual Volume in Patients Taking GLP1 Receptor Agonists,https://clinicaltrials.gov/study/NCT07006142,2. RAS + Colon,RECRUITING
NCT07007728,Iparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver Metastasis,https://clinicaltrials.gov/study/NCT07007728,2. RAS + Colon,NOT_YET_RECRUITING
NCT07009145,QL1706 Plus Bevacizumab for Unresectable or Metastatic MSI-H/dMMR CRC,https://clinicaltrials.gov/study/NCT07009145,2. RAS + Colon,NOT_YET_RECRUITING
NCT07012031,Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation,https://clinicaltrials.gov/study/NCT07012031,2. RAS + Colon,RECRUITING
NCT07012954,ctDNA-Guided Cetuximab or Bevacizumab Plus Trifluridine/Tipiracil in RAS/BRAF Wild-Type mCRC,https://clinicaltrials.gov/study/NCT07012954,2. RAS + Colon,RECRUITING
NCT07025850,Efficacy Study of Digoxin Combined With Serplulimab and Chemotherapy in First-Line Treatment of MSS Advanced Colorectal Cancer,https://clinicaltrials.gov/study/NCT07025850,2. RAS + Colon,NOT_YET_RECRUITING
NCT07044908,TQB2922 and TAS-102 Tablets for Injection With or Without Bevacizumab in Chemotherapy-failed RAS/BRAF Wild-type Advanced Colorectal Cancer,https://clinicaltrials.gov/study/NCT07044908,2. RAS + Colon,RECRUITING
NCT07051785,Fruquintinib vs Bevacizumab Combined With Irinotecan Liposome and Capecitabine as Second-Line Therapy for Advanced Metastatic Colorectal Cancer,https://clinicaltrials.gov/study/NCT07051785,2. RAS + Colon,NOT_YET_RECRUITING
NCT07056777,Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Cancer,https://clinicaltrials.gov/study/NCT07056777,2. RAS + Colon,RECRUITING
NCT07059338,Dual EGFR/HER2 Blockade Combined With Irinotecan for the Treatment of HER2-Positive Metastatic Colorectal Cancer,https://clinicaltrials.gov/study/NCT07059338,2. RAS + Colon,NOT_YET_RECRUITING
NCT07059949,Short Course Radiotherapy Followed by CAPOX and Carrilizumab and Bevacizumab or Cetuximab for the Initial Treatment of Unresectable Metastatic Rectal Cancer,https://clinicaltrials.gov/study/NCT07059949,2. RAS + Colon,NOT_YET_RECRUITING
NCT07070713,Efficacy and Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Bevacizumab Both With QL1706 in First-Line Treatment of Left-Sided mCRC,https://clinicaltrials.gov/study/NCT07070713,2. RAS + Colon,NOT_YET_RECRUITING
NCT07071844,BETWEEN: Biweekly Bevacizumab + Trifluridine/Tipiracil to Reduce Grade 3-4 Neutropenia in mCRC Patients,https://clinicaltrials.gov/study/NCT07071844,2. RAS + Colon,NOT_YET_RECRUITING
NCT07076823,Safety and Efficacy of Canagliflozin in Patients With Metastatic High Microsatellite Instability (MSI-H) Colorectal Cancer,https://clinicaltrials.gov/study/NCT07076823,2. RAS + Colon,RECRUITING
NCT07082439,Pembrolizumab and Odetiglucan in Liver Predominant Metastatic Colorectal Adenocarcinoma,https://clinicaltrials.gov/study/NCT07082439,2. RAS + Colon,RECRUITING
NCT07094893,Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status,https://clinicaltrials.gov/study/NCT07094893,2. RAS + Colon,NOT_YET_RECRUITING
NCT07107230,A Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors,https://clinicaltrials.gov/study/NCT07107230,2. RAS + Colon,RECRUITING
NCT07108127,Efficacy and Safety of Trastuzumab Biosimilars and Pertuzumab Biosimilars Combined With Chemotherapy for Neoadjuvant Treatment of Patients With Locally Advanced HER2-positive Rectal Cancer,https://clinicaltrials.gov/study/NCT07108127,2. RAS + Colon,RECRUITING
NCT07116577,"Radiotherapy Combined QL1706, TAS-102 and Bevacizumab in mCRC",https://clinicaltrials.gov/study/NCT07116577,2. RAS + Colon,NOT_YET_RECRUITING
NCT07117435,Paclitaxel Cationic Liposome (Hepatic Arterial Infusion) in Combination With Systemic Therapy as First-Line Treatment in Colorectal Liver Metastases,https://clinicaltrials.gov/study/NCT07117435,2. RAS + Colon,RECRUITING
NCT07124884,5-fluorouracil Plus Panitumumab (Anti-EGFR) and Sotorasib (KRAS G12C Inhibitor) in First-line Treatment of Patients Non-eligible for a Doublet/Triplet Chemotherapy With Advanced Unresectab,https://clinicaltrials.gov/study/NCT07124884,2. RAS + Colon,NOT_YET_RECRUITING
NCT07130903,Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer,https://clinicaltrials.gov/study/NCT07130903,2. RAS + Colon,RECRUITING
NCT07134205,The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer,https://clinicaltrials.gov/study/NCT07134205,2. RAS + Colon,NOT_YET_RECRUITING
NCT07134998,Phase I Study of HRS-6093 in Participants With Advanced Solid Tumors Harboring KRAS G12D Mutations,https://clinicaltrials.gov/study/NCT07134998,2. G12D general,RECRUITING
NCT07145450,Master Protocol of TCR-modified T Cell Therapy Targeting HLA-restricted KRAS Antigen Administered in Adult Patients With Metastatic or Locally Advanced PDAC,https://clinicaltrials.gov/study/NCT07145450,2. G12D general,RECRUITING
NCT07148128,"Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.",https://clinicaltrials.gov/study/NCT07148128,2. RAS + Colon,RECRUITING
NCT07150247,Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer,https://clinicaltrials.gov/study/NCT07150247,2. RAS + Colon,RECRUITING
NCT07150403,Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer,https://clinicaltrials.gov/study/NCT07150403,2. RAS + Colon,NOT_YET_RECRUITING
NCT07178717,A Study to Characterize Encorafenib Plus Cetuximab as Rechallenge Treatment for BRAF V600E-mutant Metastatic Colorectal Cancer Patients After Previous Therapy With BRAF Inhibitors-based Combinations,https://clinicaltrials.gov/study/NCT07178717,2. RAS + Colon,NOT_YET_RECRUITING
NCT07198165,SCRT Followed by CAPOX + Bev ± PD-1 Inhibitor for TNT in LARC,https://clinicaltrials.gov/study/NCT07198165,2. RAS + Colon,RECRUITING
NCT07198321,"A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid Tumors",https://clinicaltrials.gov/study/NCT07198321,2. RAS + Colon,NOT_YET_RECRUITING
NCT07198841,IBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation,https://clinicaltrials.gov/study/NCT07198841,2. RAS + Colon,NOT_YET_RECRUITING
NCT07204574,"The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer",https://clinicaltrials.gov/study/NCT07204574,2. RAS + Colon,RECRUITING
NCT07209111,A Clinical Study of MK-1084 in People With Advanced Solid Tumors (MK-1084-014),https://clinicaltrials.gov/study/NCT07209111,2. RAS + Colon,RECRUITING
NCT07213570,STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer,https://clinicaltrials.gov/study/NCT07213570,2. RAS + Colon,NOT_YET_RECRUITING
NCT07223047,"A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies",https://clinicaltrials.gov/study/NCT07223047,2. RAS + Colon,NOT_YET_RECRUITING
NCT07224815,cfDNA 5mC/5hmC Biomarkers to Predict Chemotherapy Response in Metastatic Colorectal Cancer,https://clinicaltrials.gov/study/NCT07224815,2. RAS + Colon,RECRUITING
NCT07224841,Development of a cfDNA 5mC/5hmC-based Biomarker Panel to Predict Targeted Therapy Efficacy in mCRC,https://clinicaltrials.gov/study/NCT07224841,2. RAS + Colon,RECRUITING
NCT07232875,HRS 4642 Injection Combined With AG Versus Placebo Combined With AG Therapy in First-Line Advanced or Metastatic Pancreatic Cancer,https://clinicaltrials.gov/study/NCT07232875,2. G12D general,NOT_YET_RECRUITING
NCT07244705,A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC,https://clinicaltrials.gov/study/NCT07244705,2. RAS + Colon,RECRUITING
NCT07252479,Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations,https://clinicaltrials.gov/study/NCT07252479,2. RAS + Colon,NOT_YET_RECRUITING
NCT07257653,The Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With or Without Immune Checkpoint Inhibitorrs in First-line Treatment of RAS/BRAF Wild Type Unresectable Metastatic Colorectal Cancer,https://clinicaltrials.gov/study/NCT07257653,2. RAS + Colon,RECRUITING
NCT07261709,"Trifluridine/Tipiracil Plus Fruquintinib vs. Trifluridine/Tipiracil Plus Bevacizumab in Refractory Metastatic Colorectal Cancer: A Randomized, Controlled, Open-Label, Non-Inferiority Trial",https://clinicaltrials.gov/study/NCT07261709,2. RAS + Colon,NOT_YET_RECRUITING
NCT07262567,Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer,https://clinicaltrials.gov/study/NCT07262567,2. G12D general,NOT_YET_RECRUITING
NCT05379985,Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS,https://clinicaltrials.gov/study/NCT05379985,2. RAS + Colon,RECRUITING
NCT05382559,A Study of ASP3082 in Adults With Advanced Solid Tumors,https://clinicaltrials.gov/study/NCT05382559,2. G12D general,RECRUITING
NCT06179160,A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation,https://clinicaltrials.gov/study/NCT06179160,2. G12D general,RECRUITING
NCT06227377,QTX3034 in Patients With KRAS G12D Mutation,https://clinicaltrials.gov/study/NCT06227377,2. G12D general,RECRUITING
NCT06364696,A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors,https://clinicaltrials.gov/study/NCT06364696,2. G12D general,RECRUITING
NCT06385925,A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation,https://clinicaltrials.gov/study/NCT06385925,2. G12D general,RECRUITING
NCT06447662,A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.,https://clinicaltrials.gov/study/NCT06447662,2. RAS + Colon,RECRUITING
NCT06625775,Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors,https://clinicaltrials.gov/study/NCT06625775,2. RAS + Colon,RECRUITING
NCT06704724,A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.,https://clinicaltrials.gov/study/NCT06704724,2. RAS + Colon,RECRUITING
NCT07023731,A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation,https://clinicaltrials.gov/study/NCT07023731,2. G12D general,RECRUITING
